| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8297611 | Biochemical and Biophysical Research Communications | 2013 | 6 Pages |
Abstract
Though poly(ADP-ribose) polymerase 1 (PARP1) inhibitors have benefits in combination with radiotherapy in prostate cancers, few is known about the exactly role and underlying mechanism of PARP1 in combination with chemotherapy agents. Here our data revealed that inhibition of PARP1 by small interfering RNA (siRNA) could enhance docetaxel's activity against PC3 cells, which is associated with an accelerate repression of EGF/Akt/FOXO1 signaling pathway. Our results provide a novel role of PARP1 in transcription regulation of EGFR/Akt/FOXO1 signaling pathway and indicate that PARP1 siRNA combined with docetaxel can be an innovative treatment strategy to potentially improve outcomes in CRPC patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Wenqi Wu, Zhenzhen Kong, Xiaolu Duan, Hanliang Zhu, Shujue Li, Shaohua Zeng, Yeping Liang, George Iliakis, Zhiming Gui, Dong Yang,